We recently published a list of the Best Income Stocks to Invest in Now. In this article, we are going to take a look at ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

With Q4 behind us, let’s have a look at Eli Lilly (NYSE:LLY) and its peers. The branded pharmaceutical industry relies on a high-cost, high-reward business model, driven by substantial ...

I believe this is a reasonable expectation. In sum, orforglipron is expected to quickly become a major blockbuster for Eli Lilly. In Q4 and full year 2024, Eli Lilly reported revenue of ...

Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ratings for the stock. Despite broader market uncertainties, the company’s ...

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

Looking ahead, Wall Street forecasts adjusted EPS of $23.21 for fiscal 2025, representing a 78.7% increase from $12.99 in ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial.

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker ... It plans to submit orforglipron for FDA approval for obesity in Q4, and for type 2 diabetes in the first half of 2026.